Exploring the link between imaging and tumor environment in urologic cancer
Exploring the Association of Imaging and Tumor Microenvironment in Urologic Cancer Using Radiogenomic Approach（Radiogenomics-Urinary）
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT06537037
This study looks at how CT and MRI scans relate to the tumor environment and outcomes in patients with urologic cancer to see if imaging can help predict their prognosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (other) |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06537037 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to investigate how imaging data correlates with the tumor microenvironment and prognosis in patients with urologic cancer. It will involve patients treated at Wuhan Union Hospital who have undergone CT or MRI scans prior to treatment. The study will analyze the relationship between imaging characteristics and tumor biology to better understand patient outcomes. By focusing on a specific patient population over a defined period, the study seeks to provide insights into the prognostic value of imaging in urologic cancers.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who have been treated for urologic cancer and have undergone imaging scans prior to treatment.
Not a fit: Patients with poor image quality, incomplete clinical data, or other primary malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of urologic cancer prognosis and improve personalized treatment strategies.
How similar studies have performed: While the specific approach of this study is novel, similar studies exploring imaging and tumor microenvironment relationships have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients treated for urologic cancer in Wuhan Union Hospital from August 2024 to August 2027; 2. Aged \> 18 years old; 3. At least one CT scan or MRI scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion criteria： 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than urologic cancer; 4. Unclear pathological diagnosis。
Where this trial is running
Wuhan, Hubei
- Union Hospital，Tongji Medical College，Huazhong University of Science and Technology — Wuhan, Hubei, China (RECRUITING)
Study contacts
- Study coordinator: Lian Yang
- Email: yanglian@hust.edu.cn
- Phone: 18986273791
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Urologic Cancer